Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Rating) shares passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.16 and traded as low as $1.75. Bolt Biotherapeutics shares last traded at $1.78, with a volume of 75,070 shares.
Wall Street Analysts Forecast Growth
Separately, SVB Leerink downgraded shares of Bolt Biotherapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $8.00 to $4.00 in a report on Thursday, August 11th.
Bolt Biotherapeutics Price Performance
The stock’s fifty day moving average price is $2.12 and its 200-day moving average price is $2.16. The firm has a market cap of $67.00 million, a price-to-earnings ratio of -0.68 and a beta of 1.01. The company has a current ratio of 9.73, a quick ratio of 9.73 and a debt-to-equity ratio of 0.10.
Insider Activity at Bolt Biotherapeutics
Hedge Funds Weigh In On Bolt Biotherapeutics
Institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC acquired a new position in shares of Bolt Biotherapeutics in the second quarter worth $30,000. Prudential Financial Inc. acquired a new position in shares of Bolt Biotherapeutics in the second quarter worth $33,000. PDT Partners LLC acquired a new position in shares of Bolt Biotherapeutics in the first quarter worth $33,000. Occudo Quantitative Strategies LP grew its stake in shares of Bolt Biotherapeutics by 19.5% in the second quarter. Occudo Quantitative Strategies LP now owns 30,816 shares of the company’s stock worth $63,000 after acquiring an additional 5,028 shares in the last quarter. Finally, Marquette Asset Management LLC acquired a new position in shares of Bolt Biotherapeutics in the second quarter worth $130,000. Institutional investors and hedge funds own 69.25% of the company’s stock.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.
- Get a free copy of the StockNews.com research report on Bolt Biotherapeutics (BOLT)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.